- Home
- DYNC vs MGNX Comparison
DYNC vs MGNX Comparison
Compare DYNC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DYNC | MGNX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.8M | 256.8M |
| IPO Year | 2024 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DYNC | MGNX |
|---|---|---|
| Price | $10.88 | $4.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 49.4K | ★ 632.5K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.76 | $1.30 |
| 52 Week High | $10.90 | $5.08 |
Technical Indicators
Market Signals| Indicator | DYNC | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 59.55 | 49.72 |
| Support Level | $10.76 | $3.80 |
| Resistance Level | N/A | $4.38 |
| Average True Range (ATR) | 0.02 | 0.21 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 57.14 | 55.76 |
Price Performance
Historical ComparisonAbout DYNC Dynamix Corporation Class A Ordinary Shares
Dynamix Corp is a blank check company.
About MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.